Barclays lowered the firm’s price target on Bruker (BRKR) to $46 from $50 and keeps an Overweight rating on the shares. The company’s guidance was cut but Barclays is confident in the second half ramp, the analyst tells investors in a research note. The firm says Bruker’s valuation is pricing in further earnings declines.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker: Resilient Performance and Strategic Positioning Amidst 2025 Challenges
- Bruker Corporation Reports Strong Q1 2025 Revenue Growth
- Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties
- Bruker Corporation Navigates Growth Amidst Challenges
- Bruker reports Q1 EPS 47c, consensus 44c